Jeff Martin
Stock Analyst at Roth Capital
(4.33)
# 359
Out of 5,149 analysts
67
Total ratings
60.32%
Success rate
15.71%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBSI Barrett Business Services | Maintains: Buy | $54 → $42 | $27.88 | +50.65% | 6 | Feb 26, 2026 | |
| OSIS OSI Systems | Maintains: Buy | $292 → $295 | $286.67 | +2.91% | 18 | Jan 30, 2026 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $45 → $50 | $33.24 | +50.42% | 6 | Dec 9, 2025 | |
| PERI Perion Network | Reiterates: Buy | $14 → $15 | $8.74 | +65.90% | 10 | Nov 13, 2025 | |
| NSP Insperity | Maintains: Buy | $85 → $74 | $21.13 | +250.21% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $12.81 | +110.77% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $3.50 | +42.86% | 1 | May 14, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $6.11 | +47.30% | 1 | Mar 20, 2025 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $13.73 | +118.50% | 6 | Nov 5, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $0.62 | +932,693.52% | 2 | Nov 15, 2017 |
Barrett Business Services
Feb 26, 2026
Maintains: Buy
Price Target: $54 → $42
Current: $27.88
Upside: +50.65%
OSI Systems
Jan 30, 2026
Maintains: Buy
Price Target: $292 → $295
Current: $286.67
Upside: +2.91%
Bowman Consulting Group
Dec 9, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $33.24
Upside: +50.42%
Perion Network
Nov 13, 2025
Reiterates: Buy
Price Target: $14 → $15
Current: $8.74
Upside: +65.90%
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $21.13
Upside: +250.21%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $12.81
Upside: +110.77%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $3.50
Upside: +42.86%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $6.11
Upside: +47.30%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $13.73
Upside: +118.50%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $0.62
Upside: +932,693.52%